Clinical Trial Update: Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is planned to evaluate preoperative tislelizumab with cetuximab and chemotherapy followed by salvage surgery, plus adjuvant tislelizuma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Locally Recurrent Oral Squamous Cell Carcinoma
• Locally Recurrent Oropharyngeal Squamous Cell Carcinoma
• Oral Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Resectable Oral Squamous Cell Carcinoma
• Resectable Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 2 | Status: NOT_YET_RECRUITING